Caliway Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the development of drugs for aesthetic medicine and chronic inflammation. The company develops CBL-514, an investigational drug, which is in Phase 2 clinical trial for non-surgical fat reduction and Dercum’s disease, as well as for cellulite treatment. It is also developing CBA-539, which is in preclinical stage for central obesity, hyperpigmentation, and skin aging, as well as offers dietary supplements. The company was incorporated in 2012 and is based in New Taipei City, Taiwan.

Sector

Healthcare

Industry

Biotechnology

CEO

Ling, Yufang

Employees

Website

www.caliway.com.tw

IPO Date

2022-12-26

Headquarters

No.99, Xintai 5th Road, 32nd Floor – 9, Sec. 1, Xizhi District, New Taipei City 221, Taiwan

Socials

NEWSLETTER

View Data Providers

NEWSLETTER

View Data Providers

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

Caliway Biopharmaceuticals 6919

Caliway Biopharmaceuticals Earnings Call Summary

Caliway Biopharmaceuticals Earnings

Transcripts

Events

About Caliway Biopharmaceuticals Co., Ltd.

Caliway Biopharmaceuticals
6919